Ryan Marion

Ryan Marion serves as a key procurement professional within the ASPR BARDA Division of Contracts Management and Acquisition, supporting the Department of Health and Human Services’ mission to accelerate the development and scalable production of medical countermeasures against biological, chemical, radiological, and nuclear threats. He manages complex acquisition programs centered on advanced biomedical research and development, focusing on the rapid validation and manufacturing readiness of vaccines, therapeutics, diagnostics, and protective technologies. His work directly enables the nation’s public health preparedness infrastructure by facilitating timely contract awards to entities capable of delivering high-risk, high-reward scientific solutions under urgent timelines. Marion collaborates with a diverse ecosystem of research institutions, biotechnology firms, and contract research organizations specializing in translational science and GMP-scale manufacturing. While no single contractor dominates his portfolio, his procurement patterns reflect consistent engagement with entities possessing deep expertise in virology, immunology, and biocontainment systems. He fosters long-term partnerships with vendors capable of scaling from preclinical discovery through clinical supply and emergency deployment, prioritizing technical capability, regulatory compliance, and supply chain resilience over cost alone. His contracting activity shows a 100% preference for non-set-aside awards, indicating a focus on technical merit and mission-critical capability rather than socioeconomic classifications. This reflects the urgent, high-stakes nature of BARDA’s mission, where speed, scalability, and proven scientific expertise take precedence over socioeconomic set-asides, though small businesses with relevant capabilities are not excluded from competition. Marion’s acquisitions are exclusively classified under NAICS 541714—Research and Development in Biotechnology—underscoring his specialization in early- to mid-stage biotech innovation. He procures services including target identification, preclinical validation, clinical trial material production, and analytical method development, with a strong emphasis on platform technologies such as mRNA, viral vectors, and recombinant protein systems. His domain expertise lies at the intersection of federal biomedical procurement and cutting-edge life sciences R&D.